Fmr LLC Purchases 39,204 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)

Fmr LLC raised its position in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 21.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 225,113 shares of the biotechnology company’s stock after buying an additional 39,204 shares during the quarter. Fmr LLC owned about 0.20% of Coherus BioSciences worth $234,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Nisa Investment Advisors LLC raised its stake in Coherus BioSciences by 2,672.8% during the second quarter. Nisa Investment Advisors LLC now owns 20,657 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 19,912 shares during the last quarter. TIAA Trust National Association bought a new position in shares of Coherus BioSciences during the second quarter valued at $47,000. Hsbc Holdings PLC raised its position in shares of Coherus BioSciences by 10.6% in the 2nd quarter. Hsbc Holdings PLC now owns 103,183 shares of the biotechnology company’s stock worth $179,000 after purchasing an additional 9,905 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Coherus BioSciences by 605.1% in the 2nd quarter. SG Americas Securities LLC now owns 123,577 shares of the biotechnology company’s stock worth $214,000 after purchasing an additional 106,052 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in Coherus BioSciences by 19.5% in the 2nd quarter. Rhumbline Advisers now owns 154,904 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 25,241 shares in the last quarter. Institutional investors own 72.82% of the company’s stock.

Analyst Ratings Changes

CHRS has been the subject of several recent analyst reports. Robert W. Baird lifted their target price on shares of Coherus BioSciences from $4.00 to $6.00 and gave the stock an “outperform” rating in a report on Thursday, December 5th. StockNews.com lowered shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Saturday, October 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Coherus BioSciences in a research report on Wednesday, December 4th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Coherus BioSciences presently has an average rating of “Moderate Buy” and an average target price of $5.38.

Coherus BioSciences Trading Up 2.7 %

Shares of CHRS stock opened at $1.52 on Friday. Coherus BioSciences, Inc. has a 12-month low of $0.66 and a 12-month high of $3.70. The stock has a market capitalization of $175.12 million, a P/E ratio of -19.00 and a beta of 0.86. The firm’s 50 day moving average is $1.10 and its 200 day moving average is $1.30.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.